Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Depot antipsychotics are widely used in clinical practice. Long-acting formulations of second-generation antipsychotics are now being developed and introduced. Aims: To review the pharmacology, pharmacokinetics and adverse effect profiles of currently available antipsychotic long-acting injections (LAIs). Method: The psychopharmacological properties of first- and second-generation antipsychotic LAIs are reviewed using data available up to October 2008. Results: First-generation antipsychotic (FGA) LAIs are associated with a high rate of acute and chronic movement disorders. Risperidone LAI is better tolerated in this respect, but is associated with hyperprolactinaemia and weight gain. Olanzapine LAI causes weight gain and other metabolic effects but appears not to be associated with an important incidence of movement disorders. Conclusions: Dosing of LAIs is complicated by delayed release of drug, changes in plasma levels without change in dose, and by the lack of data establishing clear dose requirements. All LAIs offer the prospect of assured adherence (although patients may still default on treatment) but their use is complicated by adverse effects, complex pharmacokinetics and confusion over dose–response relationships.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Clinical Pharmacokinetics of the Depot Antipsychotics
Jann, M. W., Ereshefsky, L., & Saklad, S. R. (1985) · Clinical Pharmacokinetics · doi:10.2165/00003088-198510040-00003 · Cited by 125
Lauriello, J., Lambert, T., Andersen, S., Lin, D., Taylor, C. C., & McDonnell, D. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0512 · Cited by 120
Gefvert, O., Eriksson, B., Persson, P., Helldin, L., Björner, A., Mannaert, E., Remmerie, B., Eerdekens, M., & Nyberg, S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004924 · Cited by 119
Gharabawi, G. M., Gearhart, N. C., Lasser, R. A., Mahmoud, R. A., Zhu, Y., Mannaert, E., Naessens, I., Bossie, C. A., Kujawa, M., & Simpson, G. M. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-3 · Cited by 27
Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate
Viala, A., Ba, B., Durand, A., Gouezo, F., Hou, N., & J�rgensen, A. (1988) · Psychopharmacology · doi:10.1007/bf00174677 · Cited by 24
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Self-citationClinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
Stevens, G. L., Dawson, G., & Zummo, J. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12278 · Cited by 109
“The older typical APs are less expensive than newer atypical drugs, but they are associated with more frequent AEs, especially extrapyramidal symptoms, cognitive dulling and neurological complaints.(80,83) Fluphenazine is characterized by large interpatient variability in its PK profile, which”
BackgroundHeres, S., Reichhart, T., Hamann, J., Mendel, R., Leucht, S., & Kissling, W. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2009.12.020 · Cited by 64
Metadata
- Authors
- Taylor, D.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2009-11
- Volume
- 195
- Issue
- S52
- Pages
- s13-s19
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2115154429
- Cited by
- 114
- References
- 7
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.